Current opinion supports reassessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor type 2 (HER2) receptor in tumor tissue at the time of diagnosis of relapse to tailor appropriate therapy for each patient [3,4]. The gene discussed is ESR1; the disease is neoplasm.